MediWound Ltd. (NASDAQ:MDWD) Stock Jumps 6% in a Week: More to Come?
MediWound Ltd. (NASDAQ:MDWD) is up 6% in a week. On Tuesday, the company announced encouraging topline data from the pivotal third phase pediatric clinical study, Children Innovation Debridement Study (CIDS) NexoBrid, in treating children with severe burns. The study evaluated the safety and efficacy of NexoBrid relative to the currently available standard-of-care treatments.
CIDS met its three primary endpoints with considerable statistical significance. Most importantly, NexoBriod showed a considerable reduction in time in achieving complete eschar removal and substantial wound area that requires surgical excision while at the same time showing non-inferiority to the standard of care in the quality of scars.
Equally, the study met secondary endpoints demonstrating significant surgical excision reduction and reducing the need for autograft for deep partial burns. Also, there was a favorable trend in blood loss reduction during eschar removal. NexoBrid was well tolerated and safe. CEO Sharon Malka said that it is satisfying to see NexoBrid produce such compelling results, making it close to being available as a treatment for children with severe thermal burns. So, in the coming weeks, MDWD is a stock to watch.
Market Reaction:
On Tuesday, MDWD stock slid 2% at $4.40 with more than 4.87 million shares, compared to its average volume of 347k shares. The stock has moved within a range of $4.1500 – 4.9500 after opening the trade at $3.95. Over the past 52-week, the stock has been trading within a range of $2.9000 – 6.2200.
